Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma
Authors:
- 10 March 2022
- journal article
- research article
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 21 (5) , 485-492
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- National Institutes of Health (ZIA BC 011888)
This publication has 28 references indexed in Scilit:
- Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factorsMolecular Biology of the Cell, 2015
- Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic ReviewCancer Research and Treatment, 2015
- Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like PropertiesCancer Research, 2014
- Treatment and Prognosis for Patients With Intrahepatic CholangiocarcinomaJAMA Surgery, 2014
- Cancer stem cells in the development of liver cancerJournal of Clinical Investigation, 2013
- The Autophagy Inhibitor Verteporfin Moderately Enhances the Antitumor Activity of Gemcitabine in a Pancreatic Ductal Adenocarcinoma ModelJournal of Cancer, 2013
- Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAPGenes & Development, 2012
- Inhibition of Autophagosome Formation by the Benzoporphyrin Derivative VerteporfinJournal of Biological Chemistry, 2011
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- The Epidemiology of CholangiocarcinomaSeminars in Liver Disease, 2004